TB or Not To Be?—Sharee Basdeo—Research Fellow, Clinical Medicine, Trinity College Dublin
Finding Genius Podcast
Richard Jacobs
4.4 • 1K Ratings
🗓️ 18 June 2020
⏱️ 30 minutes
🧾️ Download transcript
Summary
As a research fellow in clinical medicine, Sharee Basdeo focuses primarily on tuberculosis (TB), which has co-evolved with the human immune system for thousands of years.
By tuning in, you'll discover:
- How the three general responses to TB exposure differ, and why it's been difficult to determine why only some people develop active TB disease after exposure
- What is problematic about drug therapies and the vaccine for TB
- What Basdeo believes is the next step in TB-related research
There are roughly three categories of responses to TB: a person can be exposed to TB but mount no immune response and show no signs of having been exposed, a person can be exposed and their immune system can mount an effective response which contains the TB infection and puts it in a dormant state, or a person can be exposed and develop active TB disease.
So, what determines which course of action will occur? This is a question that has yet to be answered, and one that many people are actively researching. Basdeo discusses this topic, along with many other fascinating subjects, including how those who harbor latent TB can develop active TB as they age, innate immunity, what happens when the wrong drug or wrong dose of drug is taken for TB, how the lung and gut microbiome might be related to the immune response for TB, the mutagenesis of TB and why it is difficult to kill TB, how TB finds ways to tune down the immune response to allow itself to exist undetected, and the importance of Th17 cells.
Visit https://www.tcd.ie/research/profiles/?profile=sbasdeo to learn more about Basdeo's work.
Available on Apple Podcasts: apple.co/2Os0myK
Transcript
Click on a timestamp to play from that location
| 0:00.0 | Forget frequently asked questions. |
| 0:02.0 | Common sense, common knowledge, or Google. |
| 0:05.0 | How about advice from a real genius? |
| 0:07.0 | 95% of people in any profession are good enough to be qualified and licensed. |
| 0:11.0 | 5% go above and beyond. They become very good at what they do, but only 0.1% are real Jesus. |
| 0:18.0 | Richard Jacobs has made it his life's mission to find them for you. He hunts down and interviews geniuses in every field, sleep science, |
| 0:25.7 | cancer, stem cells, ketogenic diets, and more. Here come the geniuses. This is the Finding Genius |
| 0:32.1 | podcast that Richard Jacobs. This is the Finding Genius Podcast. |
| 0:33.0 | That is Richard Jacobs. |
| 0:35.0 | Hello, this is Richard Jacobs with the Finding Genius Podcast. |
| 0:41.0 | My guest today is Sherry and Bastio. I hope I pronounce the name, right? |
| 0:45.2 | Yes, perfect. She's a research fellow in clinical medicine over there in Ireland and she's |
| 0:51.5 | been focused on tuberculosis which I guess what I've heard has been a |
| 0:55.4 | disease that has plagued man for thousands of years literally so she's at Trinity |
| 1:01.0 | College Dublin and Sherry thanks for coming. |
| 1:04.0 | You're very welcome, Richard. |
| 1:05.0 | Yeah, tell me, how did you first, I don't know, learn about tuberculosis, get interested |
| 1:10.4 | in it, and then work to research on it. |
| 1:12.6 | So my PhD and my background is actually in auto immunity. |
| 1:16.1 | So I was looking at rheumatoid arthritis and multiple sclerosis and I became very |
| 1:20.4 | interested in a kind of a lineage of cells there called TH17 so that I've been. became very |
| 1:23.0 | called THA. 17 cells that are really quite plastic. |
... |
Please login to see the full transcript.
Disclaimer: The podcast and artwork embedded on this page are from Richard Jacobs, and are the property of its owner and not affiliated with or endorsed by Tapesearch.
Generated transcripts are the property of Richard Jacobs and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.
Copyright © Tapesearch 2026.

